摘要:
The invention discloses the use of a protein with an amino acid sequence according to SEQ. ID. NO. 1 or a naturally occurring fragment or variant thereof for identifying infections with S. aureus in a human sample. More specifically, IgE molecules specific for SEQ. ID. NO. 1 are detected in the sample of the patient. Many atopic dermatitis patients have IgE specific for SEQ. ID. NO. 1.
摘要翻译:本发明公开了具有SEQ ID NO:1的氨基酸序列的蛋白质的用途。 ID。 没有。 1或其天然存在的片段或变体,用于鉴定人样品中金黄色葡萄球菌的感染。 更具体地,对SEQ ID NO:1特异性的IgE分子。 ID。 没有。 在患者样本中检测到1。 许多特应性皮炎患者对SEQ进行IgE特异性检测。 ID。 没有。 1。
摘要:
The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.
摘要:
The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.
摘要:
Method for producing derivatives of wild-type protein allergen Phl p 1 with reduced allergenic activity compared to the wild-type allergen, comprising the following steps: providing wild-type protein allergen Phl p 1, fragmenting said wild-type protein allergen into at least three fragments, wherein at least one fragment of said at least three fragments comprises at least one T-cell epitope and said at least three fragments have a reduced allergenic activity or lack allergenic activity and rejoining said at least three fragments in an order differing from the order of the fragments in the wild-type allergen.
摘要:
The present invention relates to a method for identifying hypoallergenic polypeptides and to a corresponding screening method. The invention further relates to hypoallergenic polypeptides identified by the method of the invention and to the prophylactic and therapeutic use of these polypeptides.
摘要:
Hypoallergenic mosaic antigens assembled from naturally-occurring allergens are disclosed herein. Also disclosed are methods of making such hypoallergenic mosaic antigens, particularly those derived from plant allergens such as timothy grass pollen (Phl p 1 and Phl p 2) and birch pollen (Bet v 1). In a particularly preferred embodiment, the method of making the hypoallergenic mosaic antigen involves the steps of (a) cleaving a naturally-occurring allergen into at least two, preferably at least three non-overlapping peptide fragments and (b) recombining the peptide fragments such that the mosaic antigen includes all or substantially all of the amino acids of the original naturally-occurring allergen, though in a different order.
摘要翻译:本文公开了由天然存在的变应原组装的低过敏性花叶病毒抗原。 还公开了制备这种低变应原性花叶病毒抗原的方法,特别是衍生自植物过敏原如Timothy草花粉(Phl p 1和Phl p 2)和桦树花粉(Bet v 1)的那些。 在特别优选的实施方案中,制备低变应原性镶嵌抗原的方法包括以下步骤:(a)将天然存在的变应原切割成至少两个,优选至少三个非重叠的肽片段,和(b)将肽片段 马赛克抗原包括原始天然存在的变应原的所有或基本上全部的氨基酸,尽管以不同的顺序。
摘要:
The present invention relates to a method for inducing specific long-lasting robust immunological tolerance towards at least one polypeptide derived from at least one allergen by transplanting a hematopoietic (stem) cell which is produced to display the said at least one polypeptide derived from at least one allergen.
摘要:
The present invention relates to a method for identifying hypoallergenic polypeptides and to a corresponding screening method. The invention further relates to hypoallergenic polypeptides identified by the method of the invention and to the prophylactic and therapeutic use of these polypeptides.
摘要:
Hybrid polypeptides comprising at least two different allergenic proteins or fragments thereof wherein each fragment consists of at least eight consecutive amino acids of the respective allergenic protein are disclosed. The hybrid polypeptides and polynucleotides coding therefor can be used as pharmaceutical compositions, in particular as vaccines.
摘要:
A process for the preparation of an hypoallergenic mosaic antigen derived from an allergen is disclosed whereby a) in a first step the allergen is split into at least two parts and the IgE reactivity of each part is determined and b) in a second step those parts of the allergen which have no detectable IgE reaction are combined to a mosaic antigen which comprises the amino acids of the allergen but the order of the amino acids of the mosaic antigen is different from that of the naturally occurring allergen.